AKT1 and ovarian carcinoma: They also reported that PI-3 kinase inhibitors, wortmannin and LY294002, dramatically suppressed the FN-dependent secretion of MMP-9 and inhibited Akt activation, which ultimately suppressed the invasiveness of NOM1 ovarian cancer cells [47].